---
title: "Co-Diagnostics Unveils $3 Mln Private Placement Of Shares And Warrants"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287014317.md"
description: "Co-Diagnostics, Inc. (CODX) has announced a private placement to sell 1.65 million shares and warrants for a total of approximately $3 million. The offering is set to close around May 21, 2026, with a combined price of $1.821 per share. The warrants will have an exercise price of $1.571 and will expire in five years. CODX stock closed at $1.97, up 43.80%, but is down 0.51% in the overnight market."
datetime: "2026-05-20T06:10:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287014317.md)
  - [en](https://longbridge.com/en/news/287014317.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287014317.md)
---

# Co-Diagnostics Unveils $3 Mln Private Placement Of Shares And Warrants

(RTTNews) - Co-Diagnostics, Inc. (CODX), a molecular diagnostics company, announced that it has entered into a securities purchase agreement with certain institutional investors to sell an aggregate of 1.65 million shares of common stock or pre-funded warrants, together with warrants to purchase up to an aggregate of 3.295 million shares of common stock, in a private placement.

The offering is expected to generate gross proceeds of approximately $3 million and is scheduled to close on or about May 21, 2026.

The combined offering price for each share of common stock or pre-funded warrant, and the accompanying warrants to be issued, is $1.821.

The warrants will have an exercise price of $1.571 per share and will be exercisable immediately upon issuance, and will expire five years from the date of issuance.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

CODX has traded between $1.26 and $46.50 over the last year. The stock closed Tuesday's trade at $1.97, up 43.80%.

In the overnight market, CODX is down 0.51% at $1.96.

For more such news For More Such Biotech Stock News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [CODX.US](https://longbridge.com/en/quote/CODX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules | CODX Stock News](https://longbridge.com/en/news/286995669.md)
- [What's Going On With Co-Diagnostics Stock Wednesday?](https://longbridge.com/en/news/287091618.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Co-Diagnostics Q1 revenue rises but net loss widens](https://longbridge.com/en/news/286460572.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)